|
Group
|
Factors
|
Cut-off
|
Sen (%)
|
Spe (%)
|
PPV (%)
|
NPV (%)
|
AUC (95%CI)
|
P of AUC
|
|---|
|
Positive rate of lymph nodes
|
|
Conventional group (n = 39)
|
SCC antigen
|
≥ 6.75
|
80.0 (16/20)
|
100.0 (19/19)
|
100.0 (16/16)
|
82.6 (19/23)
|
0.893 (0.780, 1.000)
|
< 0.001
|
|
NACT group (n = 64)
|
ISCC
|
≥ 3.90
|
80.8 (21/26)
|
47.4 (18/38)
|
51.2 (21/41)
|
78.3 (18/23)
|
0.677 (0.543, 0.810)
|
0.017
|
|
SSCC
|
≥ 2.10
|
73.1 (19/26)
|
71.1 (27/38)
|
63.3 (19/30)
|
79.4 (27/34)
|
0.739 (0.610, 0.869)
|
0.001
|
|
FSCC
|
≥ 1.45
|
80.8 (21/26)
|
50.0 (19/38)
|
52.5 (21/40)
|
79.2 (19/24)
|
0.634 (0.495, 0.773)
|
0.071
|
|
TSCC
|
≥ 1.55
|
76.9 (20/26)
|
57.9 (22/38)
|
55.6 (20/36)
|
78.6 (22/28)
|
0.655 (0.519, 0.791)
|
0.036
|
|
Survival times
|
|
Conventional group (n = 39)
|
SCC
|
≤ 3.45
|
80.0 (4/5)
|
67.6 (23/34)
|
26.7 (4/15)
|
95.8 (23/24)
|
0.656 (0.359, 0.953)
|
0.266
|
|
NACT group (n = 63)
|
ISCC
|
≥ 4.55
|
100.0 (11/11)
|
57.7 (30/52)
|
33.3 (11/33)
|
100.0 (30/30)
|
0.798 (0.679, 0.917)
|
0.002
|
|
SSCC
|
≥ 2.70
|
81.8 (9/11)
|
71.2 (37/52)
|
37.5 (9/24)
|
94.9 (37/39)
|
0.803 (0.667, 0.940)
|
0.002
|
|
OSCC
|
≥ 2.75
|
81.8 (9/11)
|
80.8 (42/52)
|
47.4 (9/19)
|
95.5 (42/44)
|
0.839 (0.730, 0.948)
|
< 0.001
|
|
FSCC
|
≥ 2.80
|
81.8 (9/11)
|
61.5 (32/52)
|
31.0 (9/29)
|
94.1 (32/34)
|
0.738 (0.585, 0.891)
|
0.014
|
|
TSCC
|
≥ 1.35
|
90.9 (10/11)
|
46.2 (24/52)
|
26.3 (10/38)
|
96.0 (24/25)
|
0.677 (0.507, 0.846)
|
0.067
|
- One patient in the NACT group had a lack of survival time. ISCC The SCC antigen level before the first chemotherapy, SSCC The SCC antigen level after the first chemotherapy, OSCC The SCC antigen level after the second chemotherapy, FSCC The absolute value of the decreased SCC antigen level after the first chemotherapy, TSCC The absolute value of the decreased SCC antigen level after total chemotherapy
